Overview

A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors

Status:
Recruiting
Trial end date:
2027-10-07
Target enrollment:
Participant gender:
Summary
This study evaluating GEN1042 will include multiple parts. In this study, GEN1042 alone (phase 1a) or GEN1042 in combination with other anticancer drug(s) (phase 1b) will be evaluated in Japanese participants. The main purpose is to assess the safety and tolerability of GEN1042 monotherapy or GEN1042 in combination in Japanese study participants with cancer.
Phase:
Phase 1
Details
Lead Sponsor:
Genmab
Collaborator:
BioNTech SE
Treatments:
Carboplatin
Fluorouracil
Pembrolizumab